OBJECTIVE: To identify new genes associated with susceptibility to rheumatoid arthritis (RA), using a 2-stage genome-wide association study. METHODS: Following a liability-based study design, we analyzed 317,503 single-nucleotide polymorphisms (SNPs) in 400 patients with RA and 400 control subjects. We selected a group of candidate SNPs for replication in an independent group of 410 patients with RA and 394 control subjects. Using data from the 3 previous genome-wide association studies in RA, we also looked for genomic regions showing evidence of common association signals. Finally, we analyzed the presence of genome-wide epistasis using the binary test implemented in the PLINK program. RESULTS: We identified several genomic regions showing evidence of genome-wide association (P < 1 x 10(-5)). In the replication analysis, we identified KLF12 SNP rs1324913 as the most strongly associated SNP (P = 0.01). In our study, we observed that this SNP showed higher significance than PTPN22 SNP rs2476601, in both the genome-wide association studies and the replication analyses. Furthermore, the integration of our data with those from previous genome-wide association studies showed that KLF12 and PTPRT are the unique loci that are commonly associated in 3 different studies (P = 0.004 and P = 0.002 for KLF12 in the Wellcome Trust Case Control Consortium study and the Brigham and Women's Rheumatoid Arthritis Sequential Study genome-wide association study, respectively). The genome-wide epistasis analysis identified several SNP pairs close to significance after multiple test correction. CONCLUSION: The present genome-wide association study identified KLF12 as a new susceptibility gene for RA. The joint analysis of our results and those from previous genome-wide association studies showed genomic regions with a higher probability of being genuine susceptibility loci for RA.
OBJECTIVE: To identify new genes associated with susceptibility to rheumatoid arthritis (RA), using a 2-stage genome-wide association study. METHODS: Following a liability-based study design, we analyzed 317,503 single-nucleotide polymorphisms (SNPs) in 400 patients with RA and 400 control subjects. We selected a group of candidate SNPs for replication in an independent group of 410 patients with RA and 394 control subjects. Using data from the 3 previous genome-wide association studies in RA, we also looked for genomic regions showing evidence of common association signals. Finally, we analyzed the presence of genome-wide epistasis using the binary test implemented in the PLINK program. RESULTS: We identified several genomic regions showing evidence of genome-wide association (P < 1 x 10(-5)). In the replication analysis, we identified KLF12 SNP rs1324913 as the most strongly associated SNP (P = 0.01). In our study, we observed that this SNP showed higher significance than PTPN22 SNP rs2476601, in both the genome-wide association studies and the replication analyses. Furthermore, the integration of our data with those from previous genome-wide association studies showed that KLF12 and PTPRT are the unique loci that are commonly associated in 3 different studies (P = 0.004 and P = 0.002 for KLF12 in the Wellcome Trust Case Control Consortium study and the Brigham and Women's Rheumatoid Arthritis Sequential Study genome-wide association study, respectively). The genome-wide epistasis analysis identified several SNP pairs close to significance after multiple test correction. CONCLUSION: The present genome-wide association study identified KLF12 as a new susceptibility gene for RA. The joint analysis of our results and those from previous genome-wide association studies showed genomic regions with a higher probability of being genuine susceptibility loci for RA.
Authors: Marylyn D Ritchie; Joshua C Denny; Dana C Crawford; Andrea H Ramirez; Justin B Weiner; Jill M Pulley; Melissa A Basford; Kristin Brown-Gentry; Jeffrey R Balser; Daniel R Masys; Jonathan L Haines; Dan M Roden Journal: Am J Hum Genet Date: 2010-04-01 Impact factor: 11.025
Authors: Hae Jin Hu; Eun Heui Jin; Seon Hee Yim; So Young Yang; Seung Hyun Jung; Seung Hun Shin; Wan Uk Kim; Seung Cheol Shim; Tai Gyu Kim; Yeun Jun Chung Journal: Exp Mol Med Date: 2011-11-30 Impact factor: 8.718
Authors: D L Armstrong; A Reiff; B L Myones; F P Quismorio; M Klein-Gitelman; D McCurdy; L Wagner-Weiner; E Silverman; J O Ojwang; K M Kaufman; J A Kelly; J T Merrill; J B Harley; S-C Bae; T J Vyse; G S Gilkeson; P M Gaffney; K L Moser; C Putterman; J C Edberg; E E Brown; J Ziegler; C D Langefeld; R Zidovetzki; C O Jacob Journal: Genes Immun Date: 2009-05-14 Impact factor: 2.676
Authors: Bamidele O Tayo; Yulan Liang; Arpad Kelemen; Austin Miller; Maurizio Trevisan; Richard S Cooper Journal: BMC Med Genet Date: 2009-12-21 Impact factor: 2.103
Authors: Holger Kirsten; Elisabeth Petit-Teixeira; Markus Scholz; Dirk Hasenclever; Helene Hantmann; Dirk Heider; Ulf Wagner; Ulrich Sack; Vitor Hugo Teixeira; Bernard Prum; Jana Burkhardt; Céline Pierlot; Frank Emmrich; François Cornelis; Peter Ahnert Journal: Arthritis Res Ther Date: 2009-05-01 Impact factor: 5.156
Authors: Antonio Julià; Alba Erra; Carles Palacio; Carlos Tomas; Xavier Sans; Pere Barceló; Sara Marsal Journal: PLoS One Date: 2009-10-22 Impact factor: 3.240